"Fold Here"-Chemical Correctors in the Treatment of Epilepsy.
作者信息
Hartman Adam L
出版信息
Epilepsy Curr. 2015 Nov-Dec;15(6):340-1. doi: 10.5698/1535-7511-15.6.340.
Abstract
摘要
相似文献
1
"Fold Here"-Chemical Correctors in the Treatment of Epilepsy.
Epilepsy Curr. 2015 Nov-Dec;15(6):340-1. doi: 10.5698/1535-7511-15.6.340.
2
Energy correctors for accurate prediction of molecular energies.
J Phys Chem A. 2006 Jan 26;110(3):1060-4. doi: 10.1021/jp055460z.
3
An overview on chemical structures as ΔF508-CFTR correctors.
Eur J Med Chem. 2019 Oct 15;180:430-448. doi: 10.1016/j.ejmech.2019.07.037. Epub 2019 Jul 15.
4
Development of Cs and Cc correctors for transmission electron microscopy.
Microscopy (Oxf). 2013 Feb;62(1):23-41. doi: 10.1093/jmicro/dfs134. Epub 2013 Feb 5.
5
Comparison of lens and Fresnel null correctors.
Appl Opt. 2001 Aug 1;40(22):3688-97. doi: 10.1364/ao.40.003688.
6
Evaluation of residual aberration in fifth-order geometrical aberration correctors.
Microscopy (Oxf). 2018 Jun 1;67(3):156-163. doi: 10.1093/jmicro/dfy009.
7
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Int J Mol Sci. 2019 Nov 1;20(21):5463. doi: 10.3390/ijms20215463.
8
Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.
Arch Pharm (Weinheim). 2016 Feb;349(2):112-23. doi: 10.1002/ardp.201500352. Epub 2015 Dec 23.
9
Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
Biochemistry. 2009 Oct 20;48(41):9882-90. doi: 10.1021/bi9004842.
10
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Expert Opin Ther Pat. 2015;25(9):991-1002. doi: 10.1517/13543776.2015.1045878. Epub 2015 May 15.
本文引用的文献
1
Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy.
Nat Med. 2015 Jan;21(1):19-26. doi: 10.1038/nm.3759. Epub 2014 Dec 8.
2
New and emerging HDAC inhibitors for cancer treatment.
J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2.
3
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26.
4
Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission.
Science. 2006 Sep 22;313(5794):1792-5. doi: 10.1126/science.1129947.
5
LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures.
Ann Neurol. 2002 Sep;52(3):364-7. doi: 10.1002/ana.10280.
6
Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy.
Hum Mol Genet. 2002 May 1;11(9):1119-28. doi: 10.1093/hmg/11.9.1119.
7
Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features.
Nat Genet. 2002 Mar;30(3):335-41. doi: 10.1038/ng832. Epub 2002 Jan 28.
8
Inhibitors of histone deacetylase as new anticancer agents.
Curr Med Chem. 2001 Oct;8(12):1505-11. doi: 10.2174/0929867013372058.
9
Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency.
Metabolism. 1993 Oct;42(10):1336-9. doi: 10.1016/0026-0495(93)90135-b.
Zotero 插件